Physician profile
Michael E Janssen
NPI 1922083310
$172,754.73
in general payments reported to CMS, 2019-2025
15 companies · $15K in 2025
The $15K reported for 2025 was more than what 75% of Orthopaedic Surgery of The Spine providers received nationally (typical 2025 total: $2,116).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $19K · 2021: $41K · 2022: $58K · 2023: $691 · 2024: $27K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $41K · Food and Beverage: $1,022 · Travel and Lodging: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $41,045.21 |
| Food and Beverage | $1,021.96 |
| Travel and Lodging | $966.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Centinel Spine, LLC | $121,025.51 | 2020-2025 | Prodisc L, Prodisc C Sk |
| Precision Spine, INC. | $40,903.85 | 2019-2022 | |
| Cerapedics INC. | $10,026.56 | 2019 | |
| Bioventus LLC | $425.27 | 2019-2022 | |
| Ulrich Medical USA, INC. | $87.48 | 2020 | |
| Globus Medical, INC. | $87.22 | 2019 | |
| Depuy Synthes Sales INC. | $62.46 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $42.26 | 2023 | Iovera |
| Spineology INC. | $33.82 | 2019-2022 | |
| Titan Spine, LLC | $23.32 | 2019 | |
| Amgen INC. | $19.78 | 2025 | Krystexxa |
| Ossur Americas, INC. | $17.20 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$654,247.06 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Janssen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.